573rd MEETING, HULL 377 detection reagents used (exposure to T2 vapour, reaction with rhodamine B, fluorescence under U.V. light and photolytic decomposition to give a dark spot on prolonged exposure to U.V. light at 254nm). When analysed by gas chromatography on a 1.5m column of 3 % OV-1 on 100-120 mesh diatomite in a Pye 104 gas chromatograph, a component was observed with the same retention time as phyloquinone; however, subsequent analysis of this component by mass spectrometry indicated that it was not phyloquinone (although phyloquinonecould be present as aminor component). Further, the absorption spectrum of the material in the high-pressure liquid-chromatography peak did not contain the maxima at 243, 249, 260, 263 and 325nm characteristic of phyloquinone. In contrast, the fluorescence spectrum indicated the presence of material with an emission maximum at 466nm with excitation at 406nm (an emission characteristic of phyloquinone).
detection reagents used (exposure to T2 vapour, reaction with rhodamine B, fluorescence under U.V. light and photolytic decomposition to give a dark spot on prolonged exposure to U.V. light at 254nm). When analysed by gas chromatography on a 1.5m column of 3 % OV-1 on 100-120 mesh diatomite in a Pye 104 gas chromatograph, a component was observed with the same retention time as phyloquinone; however, subsequent analysis of this component by mass spectrometry indicated that it was not phyloquinone (although phyloquinonecould be present as aminor component). Further, the absorption spectrum of the material in the high-pressure liquid-chromatography peak did not contain the maxima at 243, 249, 260, 263 and 325nm characteristic of phyloquinone. In contrast, the fluorescence spectrum indicated the presence of material with an emission maximum at 466nm with excitation at 406nm (an emission characteristic of phyloquinone).
Thus we have so far failed to identify the hydrogen acceptor in faeces. In all chromatographic systems its behaviour is similar to that of phyloquinone, but it does not have the corresponding u.v.-absorption spectrum.
We are grateful to the Cancer Research Campaign for their financial support of this work. Utilization of cholesterol by micro-organisms under both aerobic and anaerobic conditions is well established. The first identification of products of cholesterol degradation was presented by Horvath & Krimli (1947) , who demonstrated the production of cholestenone and 7-dehydrocholesterol by a species of Azotobacter. Turfitt (1948) has shown that Proactinomyces erythropolis is capable of converting cholestenone into 3-oxoetiochol-4-enoic acid, isocaproic acid and A-nor-3,5-secocholest-5-en-3-oic acid, thus suggesting them to be intermediates of cholesterol degradation.
In contrast, Whitmarsh (I 964) found that a Nocurdiusp. isolated from soil had the ability to convert cholesterol into 3-oxo-bisnorchol-4-en-22-oic acid, androst-4-ene-3,17-dione and androsta-l,4-diene-3,17-dione. Nagasawa et al. Cholest-4-en-3-one " *.
,'
Cholesta-l,4-dien-3-one ' By using sodium deoxycholate as sole carbon source, a strain of Escherichia coli has been isolated from the faeces of a colon-cancer patient .
Since this facultative anaerobe has the ability to degrade bile acids both aerobically and anaerobically, it was decided to study the degradation of cholesterol; Grundy et al.
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BIOCHEMICAL SOCIETY TRANSACTIONS (1968), having shown that 28-50 % of ['4C]cholesterol fed daily to four patients until the isotopic steady state was reached, could not be accounted for in the liver, blood plasma, urine and faeces.
The organism, although having the ability to grow on solid cholesterol medium, is unable to grow on the sterol in liquid medium. The aerobic metabolism of cholesterol was therefore carried out in buffered mineral salts medium impregnated with 0.4 % Agar number 1 . The medium contained (g/litre): K2HP04 (7.0); KH,P04 (3.0); (NH4),S04 (1.0); NaCl(2.0); nicotinic acid (0.01); biotin (0.0125); MgSO4,7Hz0 (0.1); CaCI, (dried) (0.01); FeS04 (0.005); cholesterol (0.50); KN03 (0.50); lOml of autoclaved rumen fluid. The final pH was 7.0. The sterol substrate was added to the nedium before sterilization as a thick creamy suspension in diethyl ether, and the rumen fluid was added after autoclaving.
The aerobic fermentations were carried out in 250mI conical flasks containing 50ml of medium. A 1 inoculum of E. coli was added aseptically to the medium and the flasks were incubated at 37°C on a gyratory shaker.
The course of the fermentation was followed daily. After 5 days incubation, growth of the organism and cholesterol degradation were detected. After acidification to (V) Fig. 1 . Reactions occurring during cholesterol degradation by E. coli pH4.0, the steroids were extracted separated, and purified as reported previously . Identification of products was achieved with reference to the U.V. and i.r. spectra and mobilities of known standards on t.1.c. and g.1.c. Retention times for g.1.c. were measured relative to Sa-cholestane, and t.1.c. analysis was performed on Kieselgel GFz54 in the solvent systems methanol/dichloromethane (1 : 19, v/v) and (1 :9, v/v). Mobilities on t.1.c. were measured relative to androsta-1,4-dien-3,17-dione. Fig. 1 shows that E. coli has the ability to dehydrogenate and carry out side-chain cleavage of cholesterol yielding four neutral products, namely cholest-4-en-3-one (11); cholesta-l,4-dien-3-one (111); androst-4-ene-3,17-dione (IV); androsta-1,4-diene-3,17-dione (V) . Pilot experiments have shown that the same organism also produced compounds (11) and (V) under anaerobic conditions. This report presents the first evidence for cholesterol side-chain cleavage by a bacterium indigenous to the human intestinal tract. Indeed, side-chain cleavage of cholesterol under anaerobic conditions has not been reported previously with any other micro-organisms.
The isolation of intermediates produced by this organism supports the work of Nagasawa et al. (1969) , who proposed that the degradation of cholesterol and other sterols occurs via the pathway in Fig. 1 . No acidic intermediates were detected. Our data thus suggest that since this particular E. coli strain has the ability to degrade cholesterol in uitro, it may also degrade this sterol in the human intestinal tract. The biochemical pathway may be different from those reported for other vertebrate intestinal organisms. Much of the cholesterol ingested in the diet is converted by intestinal bacteria into coprostanol and coprostanone, these compounds being common in faeces along with unchanged cholesterol. The presence of E. coli in the normal human intestinal tract at a concentration of up to lo6 cells/g may account for considerable degradation of cholesterol. However, the production of androstanes in viuo by the human intestinal flora would not be detected because they are absorbed in the colon. Since cholesterol introduced into the colon of guinea pigs is metabolized to oestrogens, which are then secreted in the urine (Goddard & Hill, 1974) , it is possible that androstanes produced by this E. coli from cholesterol may undergo the same fate in human beings. In patients suffering from bowel stagnation (diverticulosis and blind-loop syndrome) E. coli and Bacterioides have been shown to be present up to lo8 cells/rnl and 10" cells/ml respectively (Drasar & Hill, 1974) . It is perhaps significant that E. coli, although lower in numbers than other microflora (and Bacterioides in stagnated areas) in the normal intestine, are in close apposition with the colonicepithelium in the lumen (M. Hudson, personal communication). Thus in stagnated areas E. coli may be in contact with cholesterol for sufficient time to produce oestrogens and, by further dehydrogenation, other more potent carcinogens.
Alternatively androstanes produced by E. coli may be converted into aromatic compounds by other members of the intestinal flora. It would be interesting to discover whether or not this strain of E. coli is present in all patients suffering from colon cancer.
